Literature DB >> 24661089

Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group.

Katherine Tarlock1,2, Todd A Alonzo3,4, Pilar Palomo Moraleda5, Robert B Gerbing4, Susana C Raimondi4,6, Betsy A Hirsch4,7, Yaddanapudi Ravindranath4,8, Beverly Lange4,9, William G Woods4,10, Alan S Gamis4,11, Soheil Meshinchi1,2,4.   

Abstract

Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is a rare subtype associated with FLT3-internal tandem duplication (ITD) and poor outcomes. The clinical outcomes of paediatric patients with t(6;9) with and without FLT3-ITD treated on six consecutive cooperative trails were evaluated. In contrast to patients without t(6;9), those with t(6;9) had a significantly lower complete remission rate, higher relapse rate (RR), and poor overall survival (OS). Within t(6;9) patients, those with and without FLT3-ITD had an OS of 40% and 27% respectively (P > 0·9), demonstrating that t(6;9) is a high-risk cytogenetic feature in paediatric AML and its clinical impact is independent of the presence of FLT3-ITD.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  FLT3-ITD; acute myeloid leukaemia; clinical outcome; paediatric; t(6; 9)(p23; q34)

Mesh：

Substances：

Year:  2014        PMID： 24661089      PMCID： PMC4079767          DOI： 10.1111/bjh.12852

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  12 in total

1.  Prognostic factors for acute myeloid leukemia patients with t(6;9)(p23;q34) who underwent an allogeneic hematopoietic stem cell transplant.

Authors:  K Ishiyama; A Takami; Y Kanda; S Nakao; M Hidaka; T Maeda; T Naoe; S Taniguchi; K Kawa; T Nagamura; K Tabuchi; Y Atsuta; H Sakamaki
Journal:  Leukemia       Date:  2011-12-09       Impact factor: 11.528

2.  A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies.

Authors:  M L Slovak; H Gundacker; C D Bloomfield; G Dewald; F R Appelbaum; R A Larson; M S Tallman; J M Bennett; D L Stirewalt; S Meshinchi; C L Willman; Y Ravindranath; T A Alonzo; A J Carroll; S C Raimondi; N A Heerema
Journal:  Leukemia       Date:  2006-04-20       Impact factor: 11.528

3.  Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML.

Authors:  Martin Bornhäuser; Thomas Illmer; Markus Schaich; Silke Soucek; Gerhard Ehninger; Christian Thiede
Journal:  Blood       Date:  2007-03-01       Impact factor: 22.113

4.  Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group.

Authors:  W G Woods; N Kobrinsky; J D Buckley; J W Lee; J Sanders; S Neudorf; S Gold; D R Barnard; J DeSwarte; K Dusenbery; D Kalousek; D C Arthur; B J Lange
Journal:  Blood       Date:  1996-06-15       Impact factor: 22.113

5.  Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12.

Authors:  Christine J Harrison; Robert K Hills; Anthony V Moorman; David J Grimwade; Ian Hann; David K H Webb; Keith Wheatley; Siebold S N de Graaf; Eva van den Berg; Alan K Burnett; Brenda E S Gibson
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

6.  Clinical implications of FLT3 mutations in pediatric AML.

Authors:  Soheil Meshinchi; Todd A Alonzo; Derek L Stirewalt; Michel Zwaan; Martin Zimmerman; Dirk Reinhardt; Gertjan J L Kaspers; Nyla A Heerema; Robert Gerbing; Beverly J Lange; Jerald P Radich
Journal:  Blood       Date:  2006-08-15       Impact factor: 22.113

7.  Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

Authors:  Christian Thiede; Christine Steudel; Brigitte Mohr; Markus Schaich; Ulrike Schäkel; Uwe Platzbecker; Martin Wermke; Martin Bornhäuser; Markus Ritter; Andreas Neubauer; Gerhard Ehninger; Thomas Illmer
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

8.  Translocation (6;9)(p23;q34) in acute nonlymphocytic leukemia.

Authors:  S Schwartz; R Jiji; S Kerman; J Meekins; M M Cohen
Journal:  Cancer Genet Cytogenet       Date:  1983-10

9.  Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia.

Authors:  S Meshinchi; W G Woods; D L Stirewalt; D A Sweetser; J D Buckley; T K Tjoa; I D Bernstein; J P Radich
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

10.  Mortality in overweight and underweight children with acute myeloid leukemia.

Authors:  Beverly J Lange; Robert B Gerbing; James Feusner; Jeffrey Skolnik; Nancy Sacks; Franklin O Smith; Todd A Alonzo
Journal:  JAMA       Date:  2005-01-12       Impact factor: 56.272
View more
  20 in total

1.  NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report.

Authors:  Fabiana Ostronoff; Megan Othus; Robert B Gerbing; Michael R Loken; Susana C Raimondi; Betsy A Hirsch; Beverly J Lange; Stephen Petersdorf; Jerald Radich; Frederick R Appelbaum; Alan S Gamis; Todd A Alonzo; Soheil Meshinchi
Journal:  Blood       Date:  2014-08-21       Impact factor: 22.113

2.  t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients.

Authors:  Julie Damgaard Sandahl; Eva A Coenen; Erik Forestier; Jochen Harbott; Bertil Johansson; Gitte Kerndrup; Souichi Adachi; Anne Auvrignon; H Berna Beverloo; Jean-Michel Cayuela; Lucy Chilton; Maarten Fornerod; Valérie de Haas; Christine J Harrison; Hiroto Inaba; Gertjan J L Kaspers; Der-Cherng Liang; Franco Locatelli; Riccardo Masetti; Christine Perot; Susana C Raimondi; Katarina Reinhardt; Daisuke Tomizawa; Nils von Neuhoff; Marco Zecca; C Michel Zwaan; Marry M van den Heuvel-Eibrink; Henrik Hasle
Journal:  Haematologica       Date:  2014-01-17       Impact factor: 9.941

Review 3.  The genomics of acute myeloid leukemia in children.

Authors:  Shannon E Conneely; Rachel E Rau
Journal:  Cancer Metastasis Rev       Date:  2020-03       Impact factor: 9.264

4.  Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance.

Authors:  Alexandra M Stevens; Jennifer M Miller; Jaime O Munoz; Amos S Gaikwad; Michele S Redell
Journal:  Blood Adv       Date:  2017-08-01

Review 5.  Current Management of Childhood Acute Myeloid Leukemia.

Authors:  Jeffrey E Rubnitz
Journal:  Paediatr Drugs       Date:  2017-02       Impact factor: 3.022

6.  A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children's Oncology Group.

Authors:  L Eidenschink Brodersen; T A Alonzo; A J Menssen; R B Gerbing; L Pardo; A P Voigt; S B Kahwash; B Hirsch; S Raimondi; A S Gamis; S Meshinchi; M R Loken
Journal:  Leukemia       Date:  2016-05-02       Impact factor: 11.528

7.  Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia.

Authors:  Thomas B Alexander; Norman J Lacayo; John K Choi; Raul C Ribeiro; Ching-Hon Pui; Jeffrey E Rubnitz
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

Review 8.  Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.

Authors:  C Michel Zwaan; Edward A Kolb; Dirk Reinhardt; Jonas Abrahamsson; Souichi Adachi; Richard Aplenc; Eveline S J M De Bont; Barbara De Moerloose; Michael Dworzak; Brenda E S Gibson; Henrik Hasle; Guy Leverger; Franco Locatelli; Christine Ragu; Raul C Ribeiro; Carmelo Rizzari; Jeffrey E Rubnitz; Owen P Smith; Lillian Sung; Daisuke Tomizawa; Marry M van den Heuvel-Eibrink; Ursula Creutzig; Gertjan J L Kaspers
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

9.  Imatinib therapy in acute myeloid leukemia with DEK-NUP214 and FIP1L1-PDGFRA rearrangement: A case report.

Authors:  Yanping Yang; Hai Lin; Zhonghua Du; Ruiping Hu; Yang Tang; Xinyue Liang; Jingnan Sun; Yehui Tan
Journal:  Oncol Lett       Date:  2020-03-10       Impact factor: 2.967

Review 10.  Clinical implications of molecular markers in acute myeloid leukemia.

Authors:  Sabine Kayser; Mark J Levis
Journal:  Eur J Haematol       Date:  2018-10-23       Impact factor: 2.997
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.